19-1399938-C-T

Variant summary

Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BA1

This summary comes from the ClinGen Evidence Repository: The NM_000156.6:c.182G>A variant in GAMT is a missense variant that is predicted to cause the substitution of a glycine by a glutamate at amino acid position 61 (p.Gly61Glu). To our knowledge, this variant has not been reported among individuals with GAMT deficiency and results of functional studies are unavailable. The GrpMax filtering allele frequency (95% confidence) in gnomAD v4.1.0. is 0.01102 in the East Asian population, including 6 homozygotes. This is higher than the ClinGen CCDS VCEP threshold for BA1 (>0.003), meeting this criterion (BA1). There is a ClinVar entry for this variant (Variation ID: 328350). In summary, this variant meets the criteria to be classified as benign for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 2.0.0): BA1.(Classification approved by the ClinGen Cerebral Creatine Deficiencies Variant Curation Expert Panel on March 18, 2025) LINK:https://erepo.genome.network/evrepo/ui/classification/CA9043773/MONDO:0012999/026

Frequency

Genomes: 𝑓 0.00014 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00036 ( 5 hom. )

Consequence

GAMT
NM_000156.6 missense, splice_region

Scores

6
10
3
Splicing: ADA: 0.9948
2

Clinical Significance

Benign reviewed by expert panel U:4B:2

Conservation

PhyloP100: 7.58
Variant links:
Genes affected
GAMT (HGNC:4136): (guanidinoacetate N-methyltransferase) The protein encoded by this gene is a methyltransferase that converts guanidoacetate to creatine, using S-adenosylmethionine as the methyl donor. Defects in this gene have been implicated in neurologic syndromes and muscular hypotonia, probably due to creatine deficiency and accumulation of guanidinoacetate in the brain of affected individuals. Two transcript variants encoding different isoforms have been described for this gene. Pseudogenes of this gene are found on chromosomes 2 and 13. [provided by RefSeq, Feb 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -8 ACMG points.

BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GAMTNM_000156.6 linkc.182G>A p.Gly61Glu missense_variant, splice_region_variant Exon 2 of 6 ENST00000252288.8 NP_000147.1 Q14353-1V9HWB2
GAMTNM_138924.3 linkc.182G>A p.Gly61Glu missense_variant, splice_region_variant Exon 2 of 5 NP_620279.1 Q14353-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GAMTENST00000252288.8 linkc.182G>A p.Gly61Glu missense_variant, splice_region_variant Exon 2 of 6 1 NM_000156.6 ENSP00000252288.1 Q14353-1

Frequencies

GnomAD3 genomes
AF:
0.000138
AC:
21
AN:
152206
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00405
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000116
AC:
27
AN:
232624
Hom.:
0
AF XY:
0.0000869
AC XY:
11
AN XY:
126550
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00142
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000351
GnomAD4 exome
AF:
0.000355
AC:
516
AN:
1453434
Hom.:
5
Cov.:
33
AF XY:
0.000352
AC XY:
254
AN XY:
722390
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0129
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00
Gnomad4 OTH exome
AF:
0.000133
GnomAD4 genome
AF:
0.000138
AC:
21
AN:
152322
Hom.:
1
Cov.:
32
AF XY:
0.000228
AC XY:
17
AN XY:
74482
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00406
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000231
Hom.:
0
Bravo
AF:
0.0000227
ExAC
AF:
0.000199
AC:
24
Asia WGS
AF:
0.00144
AC:
5
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Uncertain:4Benign:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Deficiency of guanidinoacetate methyltransferase Uncertain:2Benign:2
Jan 07, 2020
Natera, Inc.
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Apr 15, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 18, 2025
ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen
Significance: Benign
Review Status: reviewed by expert panel
Collection Method: curation

The NM_000156.6:c.182G>A variant in GAMT is a missense variant that is predicted to cause the substitution of a glycine by a glutamate at amino acid position 61 (p.Gly61Glu). To our knowledge, this variant has not been reported among individuals with GAMT deficiency and results of functional studies are unavailable. The GrpMax filtering allele frequency (95% confidence) in gnomAD v4.1.0. is 0.01102 in the East Asian population, including 6 homozygotes. This is higher than the ClinGen CCDS VCEP threshold for BA1 (>0.003), meeting this criterion (BA1). There is a ClinVar entry for this variant (Variation ID: 328350). In summary, this variant meets the criteria to be classified as benign for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 2.0.0): BA1. (Classification approved by the ClinGen Cerebral Creatine Deficiencies Variant Curation Expert Panel on March 18, 2025) -

Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -

not provided Uncertain:1
Jun 10, 2020
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -

Cerebral creatine deficiency syndrome Uncertain:1
Jun 03, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 61 of the GAMT protein (p.Gly61Glu). This variant is present in population databases (rs77168423, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with GAMT-related conditions. ClinVar contains an entry for this variant (Variation ID: 328350). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.61
BayesDel_addAF
Benign
-0.13
T
BayesDel_noAF
Uncertain
0.030
CADD
Pathogenic
34
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.77
D;.;.
Eigen
Uncertain
0.59
Eigen_PC
Uncertain
0.54
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.88
D;T;D
M_CAP
Pathogenic
0.45
D
MetaRNN
Benign
0.042
T;T;T
MetaSVM
Uncertain
0.59
D
MutationAssessor
Uncertain
2.0
M;.;M
PrimateAI
Uncertain
0.71
T
PROVEAN
Pathogenic
-6.9
D;.;D
REVEL
Pathogenic
0.76
Sift
Uncertain
0.0020
D;.;T
Sift4G
Pathogenic
0.0
D;.;D
Polyphen
1.0
D;.;.
Vest4
0.74
MVP
0.97
MPC
0.37
ClinPred
0.32
T
GERP RS
4.0
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.8
Varity_R
0.92
gMVP
0.64

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
0.99
dbscSNV1_RF
Pathogenic
0.86
SpliceAI score (max)
0.13
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs77168423; hg19: chr19-1399937; API